The magnitude of increased fracture risk with anti-depressant use described here is in line with findings from other epidemiological studies [9, 15–17, 24]. Those studies that compared risk with SSRIs AC220 chemical structure and TCAs [9, 15, 16] similarly reported no difference in risk. There is also evidence to support our observation of an increased risk during the initial period of exposure [15, 16]. Richards et al. [17] investigated fracture risk with SSRIs and reported a dose effect and
a sustained elevation in risk with prolonged use. Vestergaard et al. reported a dose-dependent increase in fracture risk for sedating TCAs and most SSRIs. Furthermore, they also found an association between the increase in risk of any fracture and the inhibition of the serotonin transporter system [24]. We observed
BIX 1294 chemical structure a similar increase in fracture risk for users of SSRIs and TCAs. The explanation for that increased fracture risk may be related simply to an increase in the risk of falls associated with anti-depressant use, especially as there is evidence to suggest that both SSRIs and TCAs are associated with an increased risk of fall. A large study of nursing home residents showed that, compared with non-users and after adjusting for potential confounders, the risk of falls was similar in new users of TCAs and SSRIs. The association was dose dependent and the increased risk persisted through the first 180 days of use and beyond [8]. TCAs are known to inhibit cardiovascular Na+, Ca2+ and K+ channels which can lead to life-threatening arrhythmias. SSRI use has been associated with an increased Resveratrol risk of syncope [33], postural hypotension
and dizziness [34] during the early days of exposure, and both SSRIs and TCAs can affect sleep patterns [35, 36], thereby increasing the risk of falls [37]. Another explanation for the increased fracture risk observed here is the effect of anti-depressants on bone physiology. Functional 5-HT receptors are present in bone cells and 5-HT stimulates proliferation of osteoblast precursor cells in vitro [23]. There is emerging evidence from animal studies that 5-HT is involved in bone remodelling and can alter bone mineral density (BMD) [18–20, 22]. Indeed, recent findings have shown that SSRIs decrease BMD in animal Mocetinostat models [38] and humans [17, 39–41]. Such studies that compared BMD changes with different anti-depressants reported no association between TCA use and BMD [39, 40]. In a recent study of osteoporotic fractures, it was observed that the use of SSRIs (but not TCAs) in older women was independently associated with an increased rate of hip bone loss (0.82% reduction per year) [41], although there was limited information on dose and duration of use. To explore the possibility that fracture risk may be directly related to inhibition of the 5-HTT system, we grouped together the anti-depressants used according to the degree of 5-HTT inhibition afforded.